Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
NCT ID: NCT04016987
Last Updated: 2020-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
138 participants
INTERVENTIONAL
2020-09-08
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Therapeutic Efficacy and Safety Evaluation of AI in the Management of Diabetes: A RCT Trial
NCT06957093
The Evaluation of Artificial Intelligence in Lifestyle Management of Diabetic Patients in Community
NCT06118671
Diabetic Patients,Self-Efficacy,Self-Care Behaviors,Artificial Intelligence-Based
NCT06985680
Low Glycemic Diet Intervention and Community Diabetic Patients
NCT02575937
Cohort Study of Patients With Type 1 Diabetes Registered With Mobile Application in China
NCT05163054
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Sample size estimation: We propose to enroll 138 patients with type 1 diabetes (T1DM) by considering withdrawals, 69 in the smartphone app groups and 69 in the routine care group. Sample size estimation is based on hypothesized changes in the primary outcome HbA1c.
In order to ensure high quality data, two staff are responsible for the input of original data into the database to check and confirm the accuracy. When the data entered by two staff independently, the auxiliary staff decides which data to use.
Data analysis will be conducted under the intention-to-treat principle by including all the randomized patients in the data analysis. Missing data will be filled in with multiple imputation method. Any substantial difference in baseline characteristics will be adjusted with mixed-model regression analysis. Sensitivity analysis will be conducted by using per-protocol data by excluding those patients who drop out of the RCT.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Automated, Individualized Education
Subjects will be given instructions to install the patient-end App, which includes the following functions: diabetes education, patient-doctor communication, diabetes diary, peer support, reminder for blood sugar test and related abnormal results. They receive push notifications that provides recommended education materials which meet the needs of the patient by considering his/her baseline diabetes-related knowledge.
Automated structured education intervention based on an app and artificial intelligence
In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
Routine care
Subjects only receive the education provided by health-care professionals in the outpatient department
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Automated structured education intervention based on an app and artificial intelligence
In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Insulin dependence from disease onset
* Aged 18-50 years
* With a disease duration over 6 months
* With a HbA1c level over 7%
* Treated T1DM with multiple daily injections or insulin pump
* Individuals who own smartphone and are capable of using wechat or apps
Exclusion Criteria
* Being pregnant
* With mental disorders
* Have any other condition or disease that may hamper from compliance with the protocol or complication of the trial
* Already using a smartphone app for managing diabetes
* Having chronic complications including diabetic retinopathy, diabetic nephropathy or diabetic foot, diabetic neuropathy
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Xiangya Hospital of Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xia Li
Professor, Department of Endocrinology, Institute of of Metabolism and Endocrinology, Nationa Clinical Research Center for Metabolic Diseases, Second Xiangya Hospital of Central South University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xia Li, MD/PHD
Role: PRINCIPAL_INVESTIGATOR
Central South University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
Changsha, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xia Li, MD/PHD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Huang F, Wu X, Xie Y, Liu F, Li J, Li X, Zhou Z. An automated structured education intervention based on a smartphone app in Chinese patients with type 1 diabetes: a protocol for a single-blinded randomized controlled trial. Trials. 2020 Nov 23;21(1):944. doi: 10.1186/s13063-020-04835-9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI App-EC T1D 2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.